Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? Investors will be watching what Trump makes happen.
inews.co.uk on MSN
Why the new ‘triple G’ weight loss drug is different – and can be highly dangerous
People buying the peptide retatrutide online could suffer from side-effects ranging from nausea to pancreatitis ...
Gordon Ramsay sparks controversy by refusing to adjust menu for weight loss injection users. Why is he taking this fiery ...
Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05.
People with colon cancer who took GLP-1 drugs were less likely to die within 5 years than people not on GLP-1s, a new study ...
Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's ...
Mice with the same genetic variant that contributes towards red hair in people were slower to recover from wounds than their black-haired counterparts ...
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...
The study found that the five-year mortality rate was significantly lower among patients who were using GLP-1 receptor ...
Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?
The boardroom shake-up, which erupted when Novo's board Chair Helge Lund and the independent members stepped down last month ...
This episode of Pharma Pulse discusses how the FDA’s new plausible mechanism pathway, WeightWatchers’ plans to offer oral Wegovy, and emerging evidence on berberine are shaping the future of obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback